JAK inhibition in inflammatory bowel disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

JAK inhibition in inflammatory bowel disease

Published:2017-02-17 Issue:7 Volume:13 Page:693-703
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Olivera Pablo¹²,Danese Silvio³,Peyrin-Biroulet Laurent²

Affiliation:

1. Gastroenterology Section, Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina

2. INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre-lès-Nancy, France

3. Department of Gastroenterology, IBD Center, Humanitas Clinical and Research Center, Milan, Italy

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2017.1291342

Reference82 articles.

1. Inflammatory Bowel Disease

2. Long-term complications, extraintestinal manifestations, and mortality in adult Crohnʼs disease in population-based cohorts

3. Health related quality of life in inflammatory bowel disease: The impact of surgical therapy

4. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

5. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of upadacitinib in a child with refractory ulcerative colitis;Meditsinskiy sovet = Medical Council;2024-09-02

2. Sustained mucosal colonization and fecal metabolic dysfunction by Bacteroides associates with fecal microbial transplant failure in ulcerative colitis patients;Scientific Reports;2024-08-09

3. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus;Digestive and Liver Disease;2024-08

4. The role of filgotinib in ulcerative colitis and Crohn’s disease;Immunotherapy;2024-02

5. Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data;Expert Review of Gastroenterology & Hepatology;2023-12-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3